Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1281-1295
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1281
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1281
Baseline variable | P-SOX group (n = 28) | SOX group (n = 61) | P value |
Total | 5 (17.86%) | 4 (6.56%) | 0.101 |
Clavien-Dindo grading | |||
Grade I-II | 4 | 3 | 0.127 |
Fever | 2 | 1 | 0.182 |
Lung infection | 2 | 1 | 0.182 |
Pancreatic leakage | 0 | 1 | > 0.99 |
Cardiac insufficiency | 0 | 1 | > 0.99 |
Grade III | 1 | 1 | > 0.99 |
Anastomotic leakage | 1 | 1 | 0.568 |
Grade IV | 0 | 0 | NA |
Grade V | 0 | 0 | NA |
Postoperative bleeding | 94.82 ± 70.91 | 136.97 ± 119.59 | 0.020a |
Postoperative hospital stay | 11.42 ± 5.67 | 11.20 ± 4.57 | 0.964 |
- Citation: Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol 2024; 16(4): 1281-1295
- URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1281.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1281